Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 04/28/22
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 04/28/22
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial ResultsBusiness Wire • 04/14/22
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for VutrisiranBusiness Wire • 04/04/22
Alnylam: Suing Moderna, Pfizer Over LNP Technology. There May Be Method In This MadnessSeeking Alpha • 03/23/22
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and ModernaBusiness Wire • 03/17/22
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1Business Wire • 03/01/22
Alnylam Pharmaceuticals' (ALNY) CEO Yvonne Greenstreet on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/10/22
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1BBenzinga • 02/10/22
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period ActivityBusiness Wire • 02/10/22
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/08/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 01/24/22